This is why GWPH jumped last week. Their competitor had good results but not as good as the company expected. Also investors are starting to feel the paranoia of prescribing fen fen to kids. FEN FEN remember that stuff. This is great news for GWPH
Zogenix down 33% after hours on disappointing Fintepla data
Feb. 6, 2020 4:41 PMZogenix, Inc. (ZGNX)GWPHBy: Douglas W. House, SA News Editor
Zogenix (NASDAQ:ZGNX) slumps 33% after hours in reaction to its announcement of results from a Phase 3 clinical trial evaluating two doses of Fintepla (fenfluramine oral solution) (ZX008) in patients with a severe form of childhood-onset epilepsy called Lennox-Gastaut syndrome.
The company says the higher dose met the primary endpoint of the change from baseline in seizure frequency compared to placebo. Specifically, patients receiving 0.7 mg/kg/day experienced a median reduction of 26.5% in monthly drop seizure frequency versus 7.8% for control (p=0.0012). The proportion of patients with at least a 50% reduction in monthly drop seizures, a secondary endpoint, was 25.3% compared to 10.3% for placebo (p=0.0165).
The results for the lower dose (0.2 mg/kg/day) were not statistically significant.
Phase 2 data published in September 2018 showed a 53% median reduction in seizure frequency with 62% of treated patients experiencing at least a 50% drop (median dose of 0.4 mg/kg/day).
By comparison, 20 mg/kg/day of GW Pharmaceuticals' (GWPH +7.1%) Epidiolex (cannabidiol) resulted in a 44% median reduction drop seizure frequency (vs. 22% for placebo) (package insert data).
GW Pharmaceuticals (NASDAQ:GWPH), whose Epidiolex (cannabidiol) was approved for Lennox-Gastaut in June 2018, is up 9% after hours.
